• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Vyvanse for Sluggish Cognitive Tempo in ADHD
RESEARCH UPDATE

Vyvanse for Sluggish Cognitive Tempo in ADHD

August 1, 2022
Thomas Jordan, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Thomas Jordan, MD. Dr. Jordan, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

REVIEW OF: Adler LA et al, J Clin Psychiatry 2021;82(4):20m13687

STUDY TYPE: Randomized placebo-controlled trial

Patients with ADHD often also struggle with sluggish cognitive tempo (SCT). Characteristics of SCT include being prone to daydreaming, being easily bored, feeling “spacey” or lethargic, and not processing information quickly or accurately. This diagnosis—which is not found in the DSM—is controversial, and it has the most support when it occurs as a comorbidity of ADHD.

Studies of methylphenidate and atomoxetine have shown some improvement in SCT among youth with ADHD. This industry-sponsored study, which used lisdexamfetamine (Vyvanse), is the first stimulant trial for SCT in adults.

The investigators recruited 39 adults with comorbid ADHD and SCT. This was a “clean” cohort, meaning that no one had another active psychiatric disorder and no one had a lifetime history of bipolar disorder. The trial used a crossover design, in which all patients received either stimulant or placebo over a four-week treatment block, then everyone underwent a two-week washout period before switching to the other group in a second four-week treatment block. Lisdexamfetamine was started at 30 mg daily and titrated up to 70 mg daily.

The dual primary outcomes were changes in the ADHD Rating Scale and the Barkley Sluggish Cognitive Tempo Scale. In the first treatment block, lisdexamfetamine had a medium effect size (0.68) for SCT, but the stimulant had only a nonsignificant effect during the second block, possibly due to a carryover effect. When the subjects on lisdexamfetamine were switched to placebo for the second block, their average ratings for SCT did not revert to baseline, suggesting that lisdexamfetamine’s benefits may have carried over after the switch. Alternatively, the findings in the first block may have been a false positive.

Unlike the changes in SCT, subjects’ ADHD ratings showed improvements in both four-week treatment periods with lisdexamfetamine (all p = <0.05), including measures of executive functioning and functional impairment.

Side effects were what we would expect from lisdexamfetamine: decreased appetite (11%), headache (10%), and anxiety (4%). There were no serious adverse events, and only one participant withdrew due to side effects (anxiety).

CARLAT TAKE

Patients with SCT and ADHD can expect to see improvement with amphetamine-based stimulants like lisdexamfetamine. SCT by itself is not an accepted diagnosis, and we should take caution to avoid overdiagnosis.


General Psychiatry
KEYWORDS cognition side effects vyvanse
Thomas Jordan, MD

Annual Flu Vaccines

More from this author
www.thecarlatreport.com
Issue Date: August 1, 2022
SUBSCRIBE NOW
Table Of Contents
Complementary Therapy in ADHD
What Gets in the Way of Antidepressants?
Six Tips From Prescribing Psychotropics
Vyvanse for Sluggish Cognitive Tempo in ADHD
Does Vitamin B6 Prevent Postpartum Depression?
CME Post-Test - ADHD, TCPR, August 2022
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.